File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: An update on cancer after kidney transplantation

TitleAn update on cancer after kidney transplantation
Authors
Keywordscancer
kidney disease
onconephrology
Issue Date2019
PublisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/
Citation
Nephrology Dialysis Transplantation, 2019, v. 34 n. 6, p. 914-920 How to Cite?
AbstractThe emergence of onconephrology in recent years highlights the importance of the interaction between kidney disease and cancer. Chronic kidney disease (CKD) and cancer are linked with each other in different ways bidirectionally: cancer can cause CKD, whereas CKD itself may be a risk factor for cancer. Kidney transplant recipients (KTRs) have a 2- to 3-fold increased cancer risk when compared with the general population. The elevated risk covers a wide range of cancers. Some are related to CKD, including cancers of the kidney, urinary tract and thyroid, whereas others are related to oncogenic viruses that include non-Hodgkin lymphoma, cervical cancer, nonmelanoma skin cancer and Kaposi’s sarcoma. There is no standard protocol regarding how immunosuppressive drugs should be adjusted in patients who develop posttransplant cancers. However, any modification of immunosuppressive regimens should be balanced against the risk of allograft rejection or deterioration in kidney function. Cancer surveillance can be used as a strategy to improve the clinical outcome in KTRs. Although guidelines adopted in the general population have been used as the reference, a personalized approach based on individual cancer risk, life expectancy and concurrent comorbidities has to be adopted.
Persistent Identifierhttp://hdl.handle.net/10722/275731
ISSN
2019 Impact Factor: 4.531
2015 SCImago Journal Rankings: 1.780

 

DC FieldValueLanguage
dc.contributor.authorCheung, CY-
dc.contributor.authorTang, SCW-
dc.date.accessioned2019-09-10T02:48:32Z-
dc.date.available2019-09-10T02:48:32Z-
dc.date.issued2019-
dc.identifier.citationNephrology Dialysis Transplantation, 2019, v. 34 n. 6, p. 914-920-
dc.identifier.issn0931-0509-
dc.identifier.urihttp://hdl.handle.net/10722/275731-
dc.description.abstractThe emergence of onconephrology in recent years highlights the importance of the interaction between kidney disease and cancer. Chronic kidney disease (CKD) and cancer are linked with each other in different ways bidirectionally: cancer can cause CKD, whereas CKD itself may be a risk factor for cancer. Kidney transplant recipients (KTRs) have a 2- to 3-fold increased cancer risk when compared with the general population. The elevated risk covers a wide range of cancers. Some are related to CKD, including cancers of the kidney, urinary tract and thyroid, whereas others are related to oncogenic viruses that include non-Hodgkin lymphoma, cervical cancer, nonmelanoma skin cancer and Kaposi’s sarcoma. There is no standard protocol regarding how immunosuppressive drugs should be adjusted in patients who develop posttransplant cancers. However, any modification of immunosuppressive regimens should be balanced against the risk of allograft rejection or deterioration in kidney function. Cancer surveillance can be used as a strategy to improve the clinical outcome in KTRs. Although guidelines adopted in the general population have been used as the reference, a personalized approach based on individual cancer risk, life expectancy and concurrent comorbidities has to be adopted.-
dc.languageeng-
dc.publisherOxford University Press. The Journal's web site is located at http://ndt.oxfordjournals.org/-
dc.relation.ispartofNephrology Dialysis Transplantation-
dc.rightsPre-print: Journal Title] ©: [year] [owner as specified on the article] Published by Oxford University Press [on behalf of xxxxxx]. All rights reserved. Pre-print (Once an article is published, preprint notice should be amended to): This is an electronic version of an article published in [include the complete citation information for the final version of the Article as published in the print edition of the Journal.] Post-print: This is a pre-copy-editing, author-produced PDF of an article accepted for publication in [insert journal title] following peer review. The definitive publisher-authenticated version [insert complete citation information here] is available online at: xxxxxxx [insert URL that the author will receive upon publication here].-
dc.subjectcancer-
dc.subjectkidney disease-
dc.subjectonconephrology-
dc.titleAn update on cancer after kidney transplantation-
dc.typeArticle-
dc.identifier.emailTang, SCW: scwtang@hku.hk-
dc.identifier.authorityTang, SCW=rp00480-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1093/ndt/gfy262-
dc.identifier.pmid30260424-
dc.identifier.scopuseid_2-s2.0-85067125735-
dc.identifier.hkuros303438-
dc.identifier.volume34-
dc.identifier.issue6-
dc.identifier.spage914-
dc.identifier.epage920-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats